GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:0015721 | Liver | NAFLD | bile acid and bile salt transport | 10/1882 | 30/18723 | 4.67e-04 | 6.74e-03 | 10 |
GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
GO:001943911 | Liver | Cirrhotic | aromatic compound catabolic process | 202/4634 | 467/18723 | 6.93e-19 | 1.28e-16 | 202 |
GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
GO:0006787 | Liver | Cirrhotic | porphyrin-containing compound catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033015 | Liver | Cirrhotic | tetrapyrrole catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033013 | Liver | Cirrhotic | tetrapyrrole metabolic process | 24/4634 | 59/18723 | 5.06e-03 | 2.62e-02 | 24 |
GO:0042167 | Liver | Cirrhotic | heme catabolic process | 7/4634 | 11/18723 | 7.11e-03 | 3.41e-02 | 7 |
GO:0046149 | Liver | Cirrhotic | pigment catabolic process | 7/4634 | 11/18723 | 7.11e-03 | 3.41e-02 | 7 |
GO:0006778 | Liver | Cirrhotic | porphyrin-containing compound metabolic process | 20/4634 | 49/18723 | 9.60e-03 | 4.35e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLCO1B1 | SNV | Missense_Mutation | | c.970N>T | p.Gly324Cys | p.G324C | Q9Y6L6 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-63-A5MT-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | PD |
SLCO1B1 | SNV | Missense_Mutation | | c.513N>C | p.Trp171Cys | p.W171C | Q9Y6L6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-66-2758-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
SLCO1B1 | SNV | Missense_Mutation | rs139907543 | c.898G>A | p.Glu300Lys | p.E300K | Q9Y6L6 | protein_coding | tolerated(1) | benign(0.003) | TCGA-77-8140-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | SNV | Missense_Mutation | novel | c.464N>T | p.Pro155Leu | p.P155L | Q9Y6L6 | protein_coding | tolerated(0.55) | benign(0.012) | TCGA-85-7697-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
SLCO1B1 | SNV | Missense_Mutation | | c.1061N>T | p.Gly354Val | p.G354V | Q9Y6L6 | protein_coding | deleterious(0.03) | possibly_damaging(0.841) | TCGA-85-A4QQ-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | SNV | Missense_Mutation | rs747056749 | c.1563N>T | p.Leu521Phe | p.L521F | Q9Y6L6 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-90-7769-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | SNV | Missense_Mutation | novel | c.725N>A | p.Leu242Gln | p.L242Q | Q9Y6L6 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-O2-A52N-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLCO1B1 | deletion | Frame_Shift_Del | | c.1281delC | p.Phe427LeufsTer12 | p.F427Lfs*12 | Q9Y6L6 | protein_coding | | | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SLCO1B1 | deletion | Frame_Shift_Del | novel | c.1409delN | p.Glu471AsnfsTer9 | p.E471Nfs*9 | Q9Y6L6 | protein_coding | | | TCGA-58-8391-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
SLCO1B1 | deletion | Frame_Shift_Del | novel | c.962delA | p.Asn321MetfsTer2 | p.N321Mfs*2 | Q9Y6L6 | protein_coding | | | TCGA-98-A539-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | Rosuvastatin | ROSUVASTATIN | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | 135650848 | PRAVASTATIN | |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | rocuronium | ROCURONIUM | 25279974 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | ticagrelor | TICAGRELOR | 25935875 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | CLOFIBRATE | CLOFIBRATE | 16316932 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | atrasentan | ATRASENTAN | 16513443 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | rifampin | RIFAMPIN | 22562052,21709081,24420746,19374892 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | GEMFIBROZIL | GEMFIBROZIL | 16316932 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | FENOFIBRATE | FENOFIBRATE | 16316932 |
10599 | SLCO1B1 | TRANSPORTER, DRUGGABLE GENOME | | nateglinide | NATEGLINIDE | 18187595 |